Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: Dose identification using pharmacokinetic modeling and simulation

Journal of Clinical Pharmacology

Volumn 52, Issue 9, 2012, Pages 1373-1378

  Lehr, Thorsten ^a   Haertter, Sebastian ^a   Liesenfeld, Karl Heinz ^a   Staab, Alexander ^a   Clemens, Andreas ^a   Reilly, Paul A ^b   Friedman, Jeffrey ^b  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

75 mg BID; atrial fibrillation; Dabigatran etexilate; pharmacokinetic modeling and simulation; renal impairment

Indexed keywords

CREATININE; DABIGATRAN ETEXILATE;

AGED; AREA UNDER THE CURVE; ARTICLE; CREATININE CLEARANCE; DISEASE SEVERITY; DISEASE SIMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; STEADY STATE;

ANTITHROMBINS; AREA UNDER CURVE; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COMPUTER SIMULATION; HUMANS; KIDNEY DISEASES; MODELS, BIOLOGICAL; PRODRUGS; PYRIDINES;

EID: 84866008554     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011417716     Document Type: Article

References (14)

1. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007 ; 100: 1419-1426
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med. 2009 ; 361: 1139-1151
3. HariharanSMadabushiR. Clinical pharmacology basis of deriving dosing recommendations for Pradaxa in patients with severe renal impairment. J Clin Pharmacol. In press.
4. Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009 ; 119: 1363-1369
5. United States Food and Drug Administration. Draft Guidance for Industry: Pharmacokinetics in patients with impaired renal function-Study design, data analysis and impact on dosing and labeling; 2010.
6. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008 ; 36: 386-399
7. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Brit J Clin Pharmacol. 2007 ; 64: 292-303
8. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008 ; 47: 285-295
9. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008 ; 47: 47-59
10. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005 ; 45: 555-563
11. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010 ; 49: 259-268
12. Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial..:
13. DansirikulCLehrTLiesenfeldKHHaertterSStaabA. A combined pharmacometric analysis of dabigatran etexilate in healthy subjects, atrial fibrillation, and orthopedic surgery patients. In press.
14. Briefing Information for the September 20, 2010 Meeting of the Cardiovascular and Renal Drugs Advisory Committee. United States Food and Drug Administration, Sept. 20, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM247244.pdf. Accessed May 15, 2011.